Skip to content

PROPANC BIOPHARMA, INC.

PPCB

CIK 0001517681

← back to feed
Revenue (TTM)
—
Q3 May 2026
Net Income (TTM)
−$68.36M
−3,136.6% YoY Q3 May 2026
EPS Diluted (TTM)
−$13.47
+99.0% YoY Q3 May 2026
Gross Margin
—
Q3 May 2026
Operating Margin
—
Q3 May 2026
Net Margin
—
Q3 May 2026
Free Cash Flow (TTM)
−$3.02M
Q3 May 2026
Cash
$93.24K
Q3 May 2026
Total Debt
$1.01M
Q3 May 2026
Shares Outstanding
56.96M sh
Q3 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings